PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301 The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing an NDA for the use of PAX-101 (intravenous...

PaxMedica, Inc. Provides Corporate Update After IPO -PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer- -Second Independent Director, Dr. John F. Coelho, Appointed to Board of Directors in May...